ArticleFrontiers in oncology2025

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Giuseppe Salfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.